Last reviewed · How we verify
Nebivolol/valsartan combination
Nebivolol/valsartan combination works by blocking the effects of the hormone epinephrine and relaxing blood vessels, while valsartan blocks the action of angiotensin II, a potent vasoconstrictor, to lower blood pressure.
Nebivolol/valsartan combination works by blocking the effects of the hormone epinephrine and relaxing blood vessels, while valsartan blocks the action of angiotensin II, a potent vasoconstrictor, to lower blood pressure. Used for Hypertension.
At a glance
| Generic name | Nebivolol/valsartan combination |
|---|---|
| Also known as | Diovan/Bystolic |
| Sponsor | State University of New York at Buffalo |
| Drug class | Angiotensin II receptor antagonist and beta-blocker combination |
| Target | Angiotensin II receptor, beta-adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Nebivolol is a beta-blocker that inhibits the effects of epinephrine, leading to vasodilation and decreased cardiac output. Valsartan is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, to lower blood pressure. This combination of mechanisms allows for a synergistic effect in lowering blood pressure.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Headache
- Fatigue
Key clinical trials
- 24 Hour Ambulatory Cardiac Oxygen Consumption (PHASE3)
- Determination of Drug Levels for Pharmacotherapy of Heart Failure (PHASE4)
- Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy (PHASE4)
- Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients (PHASE4)
- Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension (PHASE3)
- Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension (PHASE3)
- Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: